Exagen Inc. (NASDAQ: XGN) reported Q2 EPS of ($0.21), $0.06 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $17.2 million versus the consensus estimate of $16.23 million.

For earnings history and earnings-related data on Exagen Inc. (XGN) click here.